Oxford BioDynamics Plc (LSE:OBD) has clarified that the UK National Screening Committee’s draft guidance on prostate cancer screening does not directly impact its EpiSwitch PSE test. Regardless of the recommendation, the company has achieved six straight months of record PSE sales across the US and within the UK’s private healthcare sector, underscoring growing demand and a strengthening commercial trajectory.

The company’s wider outlook remains weighed down by ongoing financial pressures, including sustained losses and negative cash flow. Technical indicators point to bearish momentum, while valuation metrics are constrained by a negative P/E ratio—collectively signalling a high-risk profile with considerable operational challenges.

More about Oxford BioDynamics

Oxford BioDynamics Plc is an international biotechnology company specialising in precision diagnostics built on its proprietary EpiSwitch® 3D genomic platform. Its product portfolio includes the EpiSwitch® PSE prostate screening test and the EpiSwitch® CiRT assay for predicting response to checkpoint inhibitor therapies. The company serves oncology, neurology, and other therapeutic areas, with operations in the UK, US, and Malaysia, and is listed on AIM.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.